Prot #OPC-41061/156-13-211: A Phase 3b, Multi-center, Open-label Trial to Evaluate the Long Term Safety of Titrated Immediate-release Tolvaptan (OPC 41061, 30 mg to 120 mg/day, Split dose) in Subjects with Autosomal Dominant Polycystic Kidney Disease

Project: Research project

Project Details

Effective start/end date2/1/157/31/19


  • Quintiles, Inc. (OPC-41061/156-13-211 // OPC-41061/156-13-211)
  • Otsuka Pharmaceutical Development & Commericalization, Inc. (OPC-41061/156-13-211 // OPC-41061/156-13-211)